Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Feb;50(2):572-9.
doi: 10.1128/AAC.50.2.572-579.2006.

Nonmolecular test for detection of low-level resistance to fluoroquinolones in Streptococcus pneumoniae

Affiliations

Nonmolecular test for detection of low-level resistance to fluoroquinolones in Streptococcus pneumoniae

Emmanuelle Varon et al. Antimicrob Agents Chemother. 2006 Feb.

Abstract

With respect to pneumococci, there is a need to detect first-step mutants with reduced fluoroquinolone (FQ) susceptibility from which second-step, resistant mutants are likely to be selected in the presence of antipneumococcal FQs. Here, we describe an interpretative disk diffusion test, of which three options are presented, that allows the distinction between first- and second-step mutants. Using five FQ disks (pefloxacin, norfloxacin, levofloxacin, ciprofloxacin, and sparfloxacin, option 1), all known mechanisms of altered FQ susceptibility found in first-step mutants (ParC, ParE, GyrA, or efflux) and in second-step mutants (ParC and GyrA or ParE and GyrA) can be accurately detected, making this option a useful epidemiological tool. Using three FQ disks (pefloxacin, norfloxacin, and levofloxacin, option 2), the most prevalent FQ-resistant mutants, but not the first-step GyrA mutants, can be detected. With only two FQ disks (norfloxacin and levofloxacin) in the third and simplest option, first-step mutants can be distinguished from second-step mutants, however, without differentiation of ParC, ParE, or efflux alterations.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Distribution of 144 low-level and high-level fluoroquinolone-resistant strains of S. pneumoniae according to their genotypes, and MICs and inhibition zone diameters of six different fluoroquinolones (panels A to F). The strains are represented by colored disks, with the disk area corresponding to the number of strains and the color corresponding to a given FQ resistance mechanism. The rectangle above the abscissa represents the zone diameter range for 1,150 susceptible strains; the mean diameter is represented by the vertical bar inside the rectangle. CLSI breakpoints when available are represented by vertical lines. The vertical dotted line represents the cutoff value proposed for the detection of low-level-resistant mutants using pefloxacin (this work) and norfloxacin (recommended by the CA-SFM).
FIG. 2.
FIG. 2.
Disk diffusion test of fluoroquinolone susceptibility for five strains with defined resistance genotypes. The corresponding phenotypes are indicated in panels A to E. The position of the fluoroquinolone disks (5 μg) is indicated in panel F; the colored rectangles include the FQ disks to be tested in each of the three options (Table 3). PEF, pefloxacin; NOR, norfloxacin; LVX, levofloxacin; CIP, ciprofloxacin; SPX, sparfloxacin.

Similar articles

Cited by

References

    1. Brenwald, N. P., M. J. Gill, and R. Wise. 1998. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2032-2035. - PMC - PubMed
    1. Brueggemann, A. B., S. L. Coffman, P. Rhomberg, H. Huynh, L. Almer, A. Nilius, R. Flamm, and G. V. Doern. 2002. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob. Agents Chemother. 46:680-688. - PMC - PubMed
    1. Chen, D. K., A. McGeer, J. C. de Azavedo, D. E. Low, et al. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341:233-239. - PubMed
    1. Davidson, R., R. Cavalcanti, J. L. Brunton, D. J. Bast, J. C. de Azavedo, P. Kibsey, C. Fleming, and D. E. Low. 2002. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N. Engl. J. Med. 346:747-750. - PubMed
    1. Davies, T. A., A. Evangelista, S. Pfleger, K. Bush, D. F. Sahm, and R. Goldschmidt. 2002. Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000. Antimicrob. Agents Chemother. 46:119-124. - PMC - PubMed

Publication types

MeSH terms